Acquiring Company
Tarsus Pharmaceuticals
Acquired Company
Alkeus Pharmaceuticals
IrvineCambridgeManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Tarsus Pharmaceuticals has entered into a definitive agreement to acquire Alkeus Pharmaceuticals for approximately $450 million upfront. This acquisition will bolster Tarsus' retina portfolio by adding gildeuretinol, currently in phase 3 trials for Stargardt disease. The deal includes milestone payments and royalties based on sales of the therapy. The transaction is expected to close in 2026.
Fundz sees it the moment Tarsus Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Alkeus Pharmaceuticals?
Alkeus Pharmaceuticals was acquired by Tarsus Pharmaceuticals, based in Irvine. The deal was reported on August 6, 2026. Tarsus Pharmaceuticals, Inc. is a company specializing in biological products. They have shown substantial growth and have strategic initiatives in place, including the recent appointment of Dr. Tarsus Pharmaceuticals is publicly traded (TARS) and operates in Manufacturing.
When did Tarsus Pharmaceuticals acquire Alkeus Pharmaceuticals?
Tarsus Pharmaceuticals's acquisition of Alkeus Pharmaceuticals was reported on August 6, 2026. Tarsus Pharmaceuticals has entered into a definitive agreement to acquire Alkeus Pharmaceuticals for approximately $450 million upfront. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Alkeus Pharmaceuticals do?
Alkeus Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is focused on developing therapies for serious diseases of the eye with high unmet need. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.